Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Arcadia Biosciences, Inc.

Ticker
RKDA
Sector
Industry
Report date
November 14, 2026
Valye AI Score

97

Very high visibility
Recent developments
Recent developments summary

Recent developments include a $4 million private placement in June 2026, strong Q3 2024 growth, termination of a merger agreement with Roosevelt Resources, and ongoing Nasdaq listing compliance challenges.

Recent developments:
  • Arcadia Biosciences announced a private placement of approximately $4 million in June 2026 [N1].
  • The company reported strong growth in Q3 2024 [N2].
  • Arcadia Biosciences received a termination notice from Roosevelt Resources in December 2025, ending their merger plans [N3].
  • Sales increased by 11 percent as reported in August 2025 [N4].
  • The company reported quarterly earnings results in May 2025 [N5].
  • Arcadia Biosciences announced Q1 2025 financial results and conference call schedule in April 2025 [N6].
  • The company initially announced a merger with Roosevelt Resources in December 2024, which caused shares to surge 105% [N7][N8].
Overview

Arcadia Biosciences, Inc. operates as a publicly listed company on the NASDAQ Capital Market under the ticker RKDA. The company has reported positive net income and earnings per share in its latest quarterly filing as of September 30, 2026. It has a board of directors with experienced executives and independent members. Arcadia has pursued strategic corporate actions including a merger agreement with Roosevelt Resources, which was later terminated. The company has demonstrated sales growth and operational progress in recent periods. It has also raised capital through a private placement in mid-2026. Arcadia is currently addressing Nasdaq listing compliance issues related to minimum bid price and stockholders' equity, with regulatory notices and plans to regain compliance including a potential reverse stock split.

Executive summary

Arcadia Biosciences, Inc. is a publicly traded company on NASDAQ Capital Market (ticker RKDA) with recent financial disclosures showing $2.84 million in cash and equivalents and a current ratio of 3.58 as of September 30, 2026. The company reported net income of $1.76 million and EPS of $0.29 for the quarter ending September 2026. Arcadia has experienced sales growth and reported strong quarterly growth in 2024. The company engaged in a merger agreement with Roosevelt Resources in late 2024, which was terminated in late 2025. In June 2026, Arcadia announced a private placement of approximately $4 million. The company faces Nasdaq listing compliance challenges related to minimum bid price and stockholders' equity requirements, with ongoing efforts including a potential reverse stock split to regain compliance. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for RKDA

Bull case model:

Arcadia Biosciences has demonstrated operational growth with reported sales increases and strong quarterly performance. The company has engaged in strategic corporate transactions and capital raises, including a private placement, which may support its business development and expansion efforts. Experienced leadership and a focused board provide governance strength. Successful resolution of Nasdaq listing compliance issues could stabilize market access and investor confidence.

Bear case model:

The company faces significant risks related to Nasdaq listing compliance, including minimum bid price and stockholders' equity requirements, with potential delisting posing liquidity and capital access challenges. The termination of the merger agreement with Roosevelt Resources may indicate strategic uncertainties. Market volatility and regulatory pressures could impact operational stability and investor perception. The company’s financial and operational performance must be monitored in the context of these risks.

Moat:

Arcadia Biosciences' moat is derived from its specialized focus in agricultural biotechnology and plant sciences, supported by its intellectual property and strategic partnerships. The company’s governance includes experienced leadership with backgrounds in finance and agriculture sectors, which supports its operational and strategic initiatives. However, the company faces challenges related to Nasdaq listing compliance, which may impact its market presence and capital access. Its ability to maintain regulatory compliance and execute strategic transactions will influence its competitive positioning.

Risks overview
Risks summary
The primary risk for Arcadia Biosciences is potential delisting from Nasdaq due to failure to meet minimum bid price and stockholders' equity requirements, which could materially affect liquidity, capital access, and investor confidence.
Risks details:

• Nasdaq Listing Compliance Risks: Arcadia Biosciences has received notices from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements. Failure to regain compliance could result in delisting, negatively impacting liquidity, market price, and capital access [S2].
• Termination of Merger Agreement: The termination of the merger agreement with Roosevelt Resources in December 2025 may affect strategic growth plans and investor confidence [N3].
• Market and Regulatory Uncertainty: Pending regulatory reviews and changes in Nasdaq listing rules create uncertainty around compliance timelines and requirements, which could affect the company’s market standing and operational flexibility [S2].

FINAL FORECAST FOR RKDA

Final take one line
Arcadia Biosciences exhibits strong operational visibility with recent growth and capital raises but faces significant Nasdaq listing compliance risks.
Final take 12 to 24 month view

Business trends: The company has shown sales growth and operational progress, including capital raises and strategic corporate actions.
Execution milestones: Key milestones include addressing Nasdaq listing compliance issues, managing merger termination impacts, and executing capital raising activities.
Key risks: Potential Nasdaq delisting due to bid price and equity deficiencies, regulatory uncertainties, and strategic execution challenges related to terminated merger agreements.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

97
LLM visibility overview
LLM Visibility known facts
  • Arcadia Biosciences, Inc. is a publicly traded company listed on the NASDAQ Capital Market under the ticker RKDA [S1].
  • As of September 30, 2026, the company reported cash and cash equivalents of $2.84 million and current assets of $4.56 million, with current liabilities of $1.27 million, resulting in a current ratio of 3.58 and a cash ratio of 2.23 [S2].
  • Net income for the quarter ended September 30, 2026, was $1.76 million with basic and diluted EPS of $0.29 per share [S2].
  • The company has a board of directors with named executives including Thomas J. Schaefer as President, CEO, and Interim CFO, and independent directors with relevant industry and financial expertise [S1].
  • Arcadia Biosciences has engaged in corporate transactions including a merger agreement with Roosevelt Resources announced in December 2024, which was later terminated as of December 2025 [N7][N8][N3].
  • The company reported sales growth of 11% as of August 2025 [N4].
  • Arcadia Biosciences reported strong Q3 2024 growth [N2].
  • The company announced a private placement of approximately $4 million in June 2026 [N1].
  • Arcadia Biosciences has faced Nasdaq listing compliance challenges including minimum bid price and stockholders' equity requirements, with ongoing efforts to regain compliance including authorization for a reverse stock split [S2].
  • The company has disclosed risks related to potential delisting from Nasdaq due to market value and bid price deficiencies, which could impact liquidity and capital access [S2].
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-06-12 | www.nasdaq.com | Arcadia Unveils Approx. $4 Mln Private Placement; Stock Down | https://www.nasdaq.com/articles/arcadia-unveils-approx-4-mln-private-placement-stock-down
  • N2 | 2026-03-29 | www.nasdaq.com | Arcadia Biosciences Reports Strong Q3 2024 Growth | https://www.nasdaq.com/articles/arcadia-biosciences-reports-strong-q3-2024-growth
  • N3 | 2025-12-26 | www.nasdaq.com | Arcadia Biosciences Receives Termination Notice From Roosevelt Resources | https://www.nasdaq.com/articles/arcadia-biosciences-receives-termination-notice-roosevelt-resources
  • N4 | 2025-08-14 | www.nasdaq.com | Arcadia Biosciences Sales Up 11 Percent | https://www.nasdaq.com/articles/arcadia-biosciences-sales-11-percent
  • N5 | 2025-05-08 | www.nasdaq.com | ARCADIA BIOSCIENCES Earnings Results: $RKDA Reports Quarterly Earnings | https://www.nasdaq.com/articles/arcadia-biosciences-earnings-results-rkda-reports-quarterly-earnings
  • N6 | 2025-04-29 | www.nasdaq.com | Arcadia Biosciences, Inc. Announces Q1 2025 Financial Results Release and Conference Call Schedule | https://www.nasdaq.com/articles/arcadia-biosciences-inc-announces-q1-2025-financial-results-release-and-conference-call
  • N7 | 2024-12-09 | www.nasdaq.com | Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105% | https://www.nasdaq.com/articles/arcadia-biosciences-merge-roosevelt-shares-surge-105
  • N8 | 2024-12-05 | www.nasdaq.com | Arcadia Biosciences to combine with Roosevelt Resources in an all-stock deal | https://www.nasdaq.com/articles/arcadia-biosciences-combine-roosevelt-resources-all-stock-deal
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine